GSK cuts drug prices by third

GlaxoSmithKline is again cutting the price of its HIV/Aids and anti-malarial drugs in developing countries.

The UK-based pharmaceuticals group said it will make cuts of 38 per cent in the price of Malarone, one of its anti-malarial drugs, and of up to 33 per cent in five of its HIV/Aids treatments, in the 63 ‘least developed nations’, as defined by the United Nations.

The move follows the substantial price reductions it announced last year (EP3, issue 3).